In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
about
Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridoneA comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research GroupIntracellular penetration and activity of gemifloxacin in human polymorphonuclear leukocytes.In vitro activity of gemifloxacin (SB 265805) against anaerobes.Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobesActivity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms.Antipneumococcal activities of gemifloxacin compared to those of nine other agentsActivities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalisPharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers.Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone.Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacinIn vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.Ion-pair spectrophotometric estimation of gemifloxacin.Two validated spectrofluorometric methods for determination of gemifloxacin mesylate in tablets and human plasma.Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group.
P2860
Q24671956-DA1DD96B-55F7-403C-A08D-005796350C81Q33593962-04059268-1480-488F-8946-F77370A887E5Q33595129-57128058-FC4C-40EB-B755-B1ECF7C2324DQ33977655-6173B16E-FBA9-48EA-9428-37B37B85E747Q33978067-EC03784D-8DF9-4494-8268-8B37F5A09B7BQ33978324-802BB8C0-A83A-476C-BC98-456D32BF3ADCQ33978679-AAC940F9-2C4A-4689-827D-75A4BFDAD8B7Q33978946-E037E37F-ED25-4039-B8BF-DDCDE14147B7Q33979750-979E558D-BB34-4FED-91EE-692717DE514AQ34513011-A74ECA8D-627D-4232-9276-D4BA2EB56016Q34680596-D4C58222-D283-4D90-A452-A4C689F5880AQ35374935-9DCF5034-A6D4-4BB0-B545-8B1F46276939Q37877492-13CAE156-1EF1-4137-9E11-D58ECBC5C521Q39478221-D5C96B04-6BF2-4434-A9D3-03742A363F35Q39537237-CDDE50BE-4319-45E9-804F-4704AF356CCAQ39651324-8CBB9AC1-9D60-448A-9F7F-B72798974BF5Q40830478-705148D3-AB1D-435D-9946-13183F0839C6Q41426318-1DC0461B-35A5-409E-8AE2-23BFCDE243CFQ42724249-05D96422-641A-4C16-A0DC-6DFF37472E62
P2860
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
@ast
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
@en
type
label
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
@ast
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
@en
prefLabel
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
@ast
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
@en
P2093
P2860
P1476
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone.
@en
P2093
P2860
P304
P407
P577
1996-06-01T00:00:00Z